Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 4/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
| ▸ | ITGAV | P06756 | 6/20 | 0.33 |
| ▸ | ITGB8 | P26012 | 4/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.32 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21428995 | 0.81 | POLB (0.46) | — | |
| SCHEMBL21428994 | 0.81 | MMP3 (0.39) | DDB1CRBNITGB3ITGAVITGB8 | |
| SCHEMBL25901357 | 0.79 | ITGB3 (0.34) | ITGB3ITGA2BITGAVITGB8ITGB6 | |
| SCHEMBL26089962 | 0.74 | CRBN (0.38) | DDB1CRBN | |
| SCHEMBL21428993 | 0.71 | L3MBTL1 (0.39) | ADAM17 | |
| SCHEMBL21430262 | 0.70 | HDAC3 (0.40) | — | |
| SCHEMBL25903249 | 0.66 | ITGB3 (0.32) | ITGB3ITGA2B | |
| SCHEMBL29392706 | 0.66 | USP30 (0.40) | DDB1CRBN | |
| SCHEMBL38665961 | 0.65 | DDB1 (0.39) | DDB1CRBN | |
| SCHEMBL6438511 | 0.62 | ITGB3 (0.41) | ITGB3ITGA2BITGAVITGB8ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713339-B2 | Macrocyclization of peptidomimetics | UNIVERSITY OF WARWICK (GB) | 2023-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713339-B2 | Macrocyclization of peptidomimetics | NGLY1, MAX, PTMA | DDB1 2415/4885CRBN 415/4885ITGB3 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.